Connection

Michael Gold to Aged

Back to Details
This is a "connection" page, showing publications Michael Gold has written about Aged.
Michael Gold
Connection Strength
3.270
Aged
  1. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
    View in: PubMed
    Score: 0.063
  2. Same-day discharge after catheter ablation in patients with atrial fibrillation in a large nationwide administrative claims database. J Cardiovasc Electrophysiol. 2021 09; 32(9):2432-2440.
    View in: PubMed
    Score: 0.062
  3. Electrical delays in quadripolar leads with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2021 09; 32(9):2498-2503.
    View in: PubMed
    Score: 0.062
  4. Impact of age on catheter ablation of premature ventricular contractions. J Cardiovasc Electrophysiol. 2021 04; 32(4):1077-1084.
    View in: PubMed
    Score: 0.061
  5. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
    View in: PubMed
    Score: 0.059
  6. Comparison of measures of ventricular delay on cardiac resynchronization therapy response. Heart Rhythm. 2020 04; 17(4):615-620.
    View in: PubMed
    Score: 0.055
  7. The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. J Cardiovasc Electrophysiol. 2019 12; 30(12):2892-2899.
    View in: PubMed
    Score: 0.055
  8. Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019 11; 16(11):1636-1644.
    View in: PubMed
    Score: 0.053
  9. Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2018 08; 11(8):e006055.
    View in: PubMed
    Score: 0.051
  10. Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block. Heart Rhythm. 2018 10; 15(10):1525-1532.
    View in: PubMed
    Score: 0.050
  11. Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol. 2018 04; 29(4):609-615.
    View in: PubMed
    Score: 0.049
  12. The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm. 2017 12; 14(12):1748-1755.
    View in: PubMed
    Score: 0.048
  13. Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. Am J Cardiol. 2017 Jul 15; 120(2):262-266.
    View in: PubMed
    Score: 0.046
  14. The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
    View in: PubMed
    Score: 0.045
  15. Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology. 2017 05; 283(2):450-459.
    View in: PubMed
    Score: 0.045
  16. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol. 2016 Sep; 142(3):413-9.
    View in: PubMed
    Score: 0.044
  17. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.044
  18. Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study. J Am Coll Cardiol. 2015 Jun 23; 65(24):2581-2588.
    View in: PubMed
    Score: 0.040
  19. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
    View in: PubMed
    Score: 0.039
  20. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2014 Jun; 25(6):624-30.
    View in: PubMed
    Score: 0.037
  21. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
    View in: PubMed
    Score: 0.036
  22. Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
    View in: PubMed
    Score: 0.035
  23. The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm. 2013 Jul; 10(7):988-93.
    View in: PubMed
    Score: 0.035
  24. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol. 2013 Apr 15; 111(8):1165-8.
    View in: PubMed
    Score: 0.034
  25. Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
    View in: PubMed
    Score: 0.034
  26. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
    View in: PubMed
    Score: 0.033
  27. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
    View in: PubMed
    Score: 0.033
  28. Acute performance of a right ventricular automatic pacing threshold algorithm for implantable defibrillators. Pacing Clin Electrophysiol. 2012 Mar; 35(3):259-68.
    View in: PubMed
    Score: 0.032
  29. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012 Apr; 23(4):359-66.
    View in: PubMed
    Score: 0.032
  30. Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm. 2012 Mar; 9(3):370-7.
    View in: PubMed
    Score: 0.031
  31. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
    View in: PubMed
    Score: 0.031
  32. Modeling Alzheimer's disease progression using the disease system analysis approach. Alzheimers Dement. 2012 Jan; 8(1):39-50.
    View in: PubMed
    Score: 0.031
  33. Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. Heart Rhythm. 2011 Jul; 8(7):1008-13.
    View in: PubMed
    Score: 0.030
  34. A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm. 2011 May; 8(5):685-91.
    View in: PubMed
    Score: 0.030
  35. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011 May; 8(5):679-84.
    View in: PubMed
    Score: 0.030
  36. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.
    View in: PubMed
    Score: 0.029
  37. Randomized comparison of defibrillation thresholds from the right ventricular apex and outflow tract. Heart Rhythm. 2010 Nov; 7(11):1561-6.
    View in: PubMed
    Score: 0.029
  38. Role of transesophageal echocardiography among patients with atrial fibrillation undergoing electrophysiology testing. Am J Cardiol. 2009 Nov 01; 104(9):1256-8.
    View in: PubMed
    Score: 0.027
  39. Acute hemodynamic effects of atrial pacing with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2009 Aug; 20(8):894-900.
    View in: PubMed
    Score: 0.026
  40. Disparities in preferences for receiving support and education among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2009 Mar; 32(3):383-90.
    View in: PubMed
    Score: 0.026
  41. Impact of atrial prevention pacing on atrial fibrillation burden: primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. Heart Rhythm. 2009 Mar; 6(3):295-301.
    View in: PubMed
    Score: 0.026
  42. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
    View in: PubMed
    Score: 0.026
  43. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation. 2008 Nov 11; 118(20):2022-8.
    View in: PubMed
    Score: 0.026
  44. Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm. 2008 Mar; 5(3):394-9.
    View in: PubMed
    Score: 0.024
  45. Atrial overdrive pacing and incidence of heart failure-related adverse events in permanently paced patients. J Interv Card Electrophysiol. 2007 Jun; 19(1):55-60.
    View in: PubMed
    Score: 0.023
  46. Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. Am J Cardiol. 2007 Jul 15; 100(2):243-6.
    View in: PubMed
    Score: 0.023
  47. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007 Mar; 68(3):430-8.
    View in: PubMed
    Score: 0.023
  48. A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2007 May; 18(5):490-6.
    View in: PubMed
    Score: 0.023
  49. Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system. J Cardiovasc Electrophysiol. 2006 Jun; 17(6):617-20.
    View in: PubMed
    Score: 0.022
  50. Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm. 2005 Apr; 2(4):376-81.
    View in: PubMed
    Score: 0.020
  51. Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. J Cardiovasc Electrophysiol. 2004 Jul; 15(7):790-4.
    View in: PubMed
    Score: 0.019
  52. Comparison of step-down and binary search algorithms for determination of defibrillation threshold in humans. Pacing Clin Electrophysiol. 2004 Feb; 27(2):218-20.
    View in: PubMed
    Score: 0.019
  53. Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
    View in: PubMed
    Score: 0.019
  54. Effect of shock polarity on defibrillation thresholds with a hybrid patch-coil lead system. J Interv Card Electrophysiol. 2003 Dec; 9(3):391-6.
    View in: PubMed
    Score: 0.018
  55. Distal right ventricular coil position reduces defibrillation thresholds. J Cardiovasc Electrophysiol. 2003 Oct; 14(10):1036-40.
    View in: PubMed
    Score: 0.018
  56. Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
    View in: PubMed
    Score: 0.017
  57. Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. Pacing Clin Electrophysiol. 2003 Jan; 26(1P2):483-6.
    View in: PubMed
    Score: 0.017
  58. Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. J Cardiovasc Electrophysiol. 2002 Nov; 13(11):1092-7.
    View in: PubMed
    Score: 0.017
  59. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002 Aug; 13(8):770-5.
    View in: PubMed
    Score: 0.017
  60. Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. Europace. 2022 07 21; 24(7):1058-1064.
    View in: PubMed
    Score: 0.017
  61. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation. 2002 Apr 30; 105(17):2043-8.
    View in: PubMed
    Score: 0.016
  62. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
    View in: PubMed
    Score: 0.016
  63. Effect of shock polarity on the efficacy of transthoracic atrial defibrillation. Am Heart J. 2002 Mar; 143(3):541-5.
    View in: PubMed
    Score: 0.016
  64. Effects of selective autonomic blockade on T-wave alternans in humans. Circulation. 2002 Feb 19; 105(7):837-42.
    View in: PubMed
    Score: 0.016
  65. A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. Am J Cardiol. 2001 Nov 01; 88(9):1043-5.
    View in: PubMed
    Score: 0.016
  66. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
    View in: PubMed
    Score: 0.016
  67. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. Circulation. 2021 11 09; 144(19):1543-1552.
    View in: PubMed
    Score: 0.016
  68. Using the years-of-healthy-life measure to calculate QALYs. Am J Prev Med. 2001 Jan; 20(1):35-9.
    View in: PubMed
    Score: 0.015
  69. Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. Can J Cardiol. 2021 05; 37(5):803-809.
    View in: PubMed
    Score: 0.015
  70. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol. 2000 Dec; 36(7):2247-53.
    View in: PubMed
    Score: 0.015
  71. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. J Drugs Dermatol. 2020 10 01; 19(10):985-991.
    View in: PubMed
    Score: 0.015
  72. Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008370.
    View in: PubMed
    Score: 0.015
  73. Bilateral Bundle Branch Area Pacing to Achieve Physiological Conduction System Activation. Circ Arrhythm Electrophysiol. 2020 08; 13(8):e008267.
    View in: PubMed
    Score: 0.014
  74. Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights From ASSERT. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008655.
    View in: PubMed
    Score: 0.014
  75. Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000 May 01; 85(9):1106-9.
    View in: PubMed
    Score: 0.014
  76. Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction. J Interv Card Electrophysiol. 2000 Apr; 4(1):301-5.
    View in: PubMed
    Score: 0.014
  77. Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. J Comp Eff Res. 2020 04; 9(5):375-385.
    View in: PubMed
    Score: 0.014
  78. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med. 2020 04; 26(4):577-588.
    View in: PubMed
    Score: 0.014
  79. Signal-averaged isoharmonic body surface maps of patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2000 Feb; 11(2):160-7.
    View in: PubMed
    Score: 0.014
  80. Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):21-4.
    View in: PubMed
    Score: 0.014
  81. Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):25-9.
    View in: PubMed
    Score: 0.014
  82. Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
    View in: PubMed
    Score: 0.014
  83. Evaluation, Management, and Outcomes of Patients Poorly Responsive to Cardiac?Resynchronization Device Therapy. J Am Coll Cardiol. 2019 11 26; 74(21):2588-2603.
    View in: PubMed
    Score: 0.014
  84. Interaction of septadian and circadian rhythms in life-threatening ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Am J Cardiol. 1999 Sep 01; 84(5):555-7.
    View in: PubMed
    Score: 0.014
  85. Cardiac arrhythmia: current therapy. Hosp Pract (1995). 1999 Sep 01; 34(9):27-8, 31-2, 35-8 passim.
    View in: PubMed
    Score: 0.014
  86. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 09 01; 30(9):1487-1495.
    View in: PubMed
    Score: 0.014
  87. Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways. J Am Coll Cardiol. 1999 Aug; 34(2):358-62.
    View in: PubMed
    Score: 0.014
  88. Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. Am Heart J. 1999 Jul; 138(1 Pt 1):133-6.
    View in: PubMed
    Score: 0.013
  89. Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circ Arrhythm Electrophysiol. 2019 04; 12(4):e006665.
    View in: PubMed
    Score: 0.013
  90. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999 Jan; 137(1):100-3.
    View in: PubMed
    Score: 0.013
  91. Reversible prolonged pacemaker failure due to electrocautery. J Interv Card Electrophysiol. 1998 Dec; 2(4):343-4.
    View in: PubMed
    Score: 0.013
  92. A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. J Interv Card Electrophysiol. 1998 Dec; 2(4):345-9.
    View in: PubMed
    Score: 0.013
  93. Inappropriate shocks from implanted cardioverter defibrillators caused by sensing of diaphragmatic myopotentials. J Interv Card Electrophysiol. 1998 Dec; 2(4):367-70.
    View in: PubMed
    Score: 0.013
  94. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
    View in: PubMed
    Score: 0.013
  95. Noninvasive tissue adhesive for cardiac implantable electronic device pocket closure: the TAPE pilot study. J Interv Card Electrophysiol. 2019 Mar; 54(2):171-176.
    View in: PubMed
    Score: 0.013
  96. Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk?of Heart Failure. J Am Coll Cardiol. 2018 06 12; 71(23):2603-2611.
    View in: PubMed
    Score: 0.013
  97. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998 Jun; 36(6):778-92.
    View in: PubMed
    Score: 0.012
  98. Comparison of Hyaluronic Acid Gel With (HARDL) and Without Lidocaine (HAJUP) in the Treatment of Moderate-To-Severe Nasolabial Folds: A Randomized, Evaluator-Blinded Study. Dermatol Surg. 2018 06; 44(6):833-840.
    View in: PubMed
    Score: 0.012
  99. Comparison of single- and dual-coil active pectoral defibrillation lead systems. J Am Coll Cardiol. 1998 May; 31(6):1391-4.
    View in: PubMed
    Score: 0.012
  100. Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). Am Heart J. 2018 07; 201:160-163.
    View in: PubMed
    Score: 0.012
  101. Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Mar; 9(3):240-4.
    View in: PubMed
    Score: 0.012
  102. Strength-duration relationship for human transvenous defibrillation. Circulation. 1997 Nov 18; 96(10):3517-20.
    View in: PubMed
    Score: 0.012
  103. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. Am J Cardiol. 1997 Oct 15; 80(8):1098-100.
    View in: PubMed
    Score: 0.012
  104. Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.012
  105. Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators. Am J Cardiol. 1997 Oct 01; 80(7):960-2.
    View in: PubMed
    Score: 0.012
  106. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. JACC Clin Electrophysiol. 2017 12 26; 3(13):1475-1483.
    View in: PubMed
    Score: 0.012
  107. Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol. 1997 Sep 01; 80(5):591-4.
    View in: PubMed
    Score: 0.012
  108. Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol. 1997 Jun 15; 79(12):1623-7.
    View in: PubMed
    Score: 0.012
  109. Distortion of intracardiac electrograms following defibrillator shocks for atrial tachyarrhythmias. Pacing Clin Electrophysiol. 1997 Jun; 20(6):1682-5.
    View in: PubMed
    Score: 0.012
  110. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017 May 01; 38(17):1339-1344.
    View in: PubMed
    Score: 0.012
  111. Effect of waveform tilt on defibrillation thresholds in humans. J Cardiovasc Electrophysiol. 1997 May; 8(5):496-501.
    View in: PubMed
    Score: 0.012
  112. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
    View in: PubMed
    Score: 0.011
  113. Chronic rise in monophasic defibrillation thresholds with a transvenous lead system. Am J Cardiol. 1997 Feb 15; 79(4):502-5.
    View in: PubMed
    Score: 0.011
  114. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
    View in: PubMed
    Score: 0.011
  115. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol. 1996 Nov 01; 28(5):1278-82.
    View in: PubMed
    Score: 0.011
  116. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol. 1996 Nov 01; 78(9):975-9.
    View in: PubMed
    Score: 0.011
  117. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2016 11; 9(11).
    View in: PubMed
    Score: 0.011
  118. Increased Monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation. 1996 Sep 15; 94(6):1346-9.
    View in: PubMed
    Score: 0.011
  119. Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. Am J Cardiol. 1996 Sep 01; 78(5):540-3.
    View in: PubMed
    Score: 0.011
  120. Chronic rise in defibrillation threshold with a hybrid lead system. Am J Cardiol. 1996 Aug 01; 78(3):309-12.
    View in: PubMed
    Score: 0.011
  121. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol. 1996 Aug 01; 78(3):313-6.
    View in: PubMed
    Score: 0.011
  122. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol. 1996 Jul 01; 78(1):47-50.
    View in: PubMed
    Score: 0.011
  123. Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. Circ Cardiovasc Imaging. 2016 May; 9(5).
    View in: PubMed
    Score: 0.011
  124. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016 05; 13(5):1066-1074.
    View in: PubMed
    Score: 0.011
  125. Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol. 1995 Oct; 26(4):967-73.
    View in: PubMed
    Score: 0.010
  126. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
    View in: PubMed
    Score: 0.010
  127. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
    View in: PubMed
    Score: 0.010
  128. Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm. 2015 Dec; 12(12):2402-10.
    View in: PubMed
    Score: 0.010
  129. Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. Am J Cardiol. 1995 Jun 01; 75(16):1158-61.
    View in: PubMed
    Score: 0.010
  130. Spurious discharges due to late insulation break in endocardial sensing leads for cardioverter defibrillators. Pacing Clin Electrophysiol. 1995 Mar; 18(3 Pt 1):478-81.
    View in: PubMed
    Score: 0.010
  131. Overdrive pacing for atrial flutter. Am J Cardiol. 1994 Nov 15; 74(10):1021-3.
    View in: PubMed
    Score: 0.010
  132. Long-term effectiveness of the combined minute ventilation and patient activity sensors as predictor of heart failure events in patients treated with cardiac resynchronization therapy: Results of the Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device Trial (CLEPSYDRA) study. Eur J Heart Fail. 2014 Jun; 16(6):663-70.
    View in: PubMed
    Score: 0.009
  133. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014 May 27; 129(21):2094-9.
    View in: PubMed
    Score: 0.009
  134. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol. 1994 Mar 01; 23(3):560-4.
    View in: PubMed
    Score: 0.009
  135. Implantable cardiovertor/defibrillator placement in a patient with amiodarone pulmonary toxicity under thoracic epidural anesthesia. Anesthesiology. 1993 Sep; 79(3):608-11.
    View in: PubMed
    Score: 0.009
  136. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013 Aug 27; 128(9):944-53.
    View in: PubMed
    Score: 0.009
  137. Health insurance and mortality. Evidence from a national cohort. JAMA. 1993 Aug 11; 270(6):737-41.
    View in: PubMed
    Score: 0.009
  138. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.009
  139. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol. 2013 Apr; 24(4):381-7.
    View in: PubMed
    Score: 0.009
  140. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail. 2012 Dec; 14(12):1420-8.
    View in: PubMed
    Score: 0.008
  141. Palliative care for patients with chronic obstructive pulmonary disease: exploring the landscape. Intern Med J. 2012 Sep; 42(9):1053-7.
    View in: PubMed
    Score: 0.008
  142. Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. Heart Rhythm. 2012 Oct; 9(10):1667-73.
    View in: PubMed
    Score: 0.008
  143. Relevance of electrical remodeling in human atrial fibrillation: results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012 Aug 01; 5(4):626-31.
    View in: PubMed
    Score: 0.008
  144. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12; 366(2):120-9.
    View in: PubMed
    Score: 0.008
  145. Acute clinical evaluation of a left ventricular automatic threshold determination algorithm based on evoked response sensing. Pacing Clin Electrophysiol. 2012 Mar; 35(3):348-56.
    View in: PubMed
    Score: 0.008
  146. Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage. 2013 Jul 15; 75:249-261.
    View in: PubMed
    Score: 0.008
  147. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.008
  148. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
    Score: 0.008
  149. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
    View in: PubMed
    Score: 0.007
  150. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.007
  151. A multi-center randomized proof-of-concept clinical trial applying [?8F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1241-56.
    View in: PubMed
    Score: 0.007
  152. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009 Nov 10; 120(19):1858-65.
    View in: PubMed
    Score: 0.007
  153. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
    View in: PubMed
    Score: 0.007
  154. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009 Jul-Aug; 25(6):469-76.
    View in: PubMed
    Score: 0.007
  155. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 02; 52(23):1834-1843.
    View in: PubMed
    Score: 0.006
  156. Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. Congest Heart Fail. 2008 Mar-Apr; 14(2):66-74.
    View in: PubMed
    Score: 0.006
  157. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
    View in: PubMed
    Score: 0.006
  158. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J. 2006 Sep; 152(3):442-7.
    View in: PubMed
    Score: 0.006
  159. Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2005 Jul; 16(7):708-13.
    View in: PubMed
    Score: 0.005
  160. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 20(2-3):120-32.
    View in: PubMed
    Score: 0.005
  161. Efficacy of transthoracic cardioversion of atrial fibrillation using a biphasic, truncated exponential shock waveform at variable initial shock energies. Am J Cardiol. 2004 Dec 15; 94(12):1572-4.
    View in: PubMed
    Score: 0.005
  162. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Oct; 95(1):157-64.
    View in: PubMed
    Score: 0.005
  163. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol. 2003 Nov; 14(11):1180-6.
    View in: PubMed
    Score: 0.005
  164. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol. 2003 Sep 17; 42(6):1098-102.
    View in: PubMed
    Score: 0.005
  165. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003 Aug 20; 42(4):627-33.
    View in: PubMed
    Score: 0.004
  166. Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. Ann Noninvasive Electrocardiol. 2003 Jul; 8(3):219-26.
    View in: PubMed
    Score: 0.004
  167. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.004
  168. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
    View in: PubMed
    Score: 0.004
  169. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000 Jun 29; 342(26):1937-45.
    View in: PubMed
    Score: 0.004
  170. No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States. Ann Neurol. 2000 May; 47(5):687.
    View in: PubMed
    Score: 0.004
  171. Alzheimers disease is not associated with the hypertension genetic risk factors PLA(2) or G protein beta3, either independently or interactively with apolipoprotein E. Am J Med Genet. 1999 Oct 15; 88(5):465-8.
    View in: PubMed
    Score: 0.003
  172. The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neurosci Lett. 1999 Aug 06; 270(3):133-6.
    View in: PubMed
    Score: 0.003
  173. No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples. Neurosci Lett. 1999 May 14; 266(3):193-6.
    View in: PubMed
    Score: 0.003
  174. Toward a broader view of values in cost-effectiveness analysis of health. Hastings Cent Rep. 1999 May-Jun; 29(3):7-15.
    View in: PubMed
    Score: 0.003
  175. Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. Circulation. 1999 Apr 13; 99(14):1843-50.
    View in: PubMed
    Score: 0.003
  176. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998 Aug 14; 252(2):95-8.
    View in: PubMed
    Score: 0.003
  177. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett. 1998 Jun 19; 249(2-3):115-8.
    View in: PubMed
    Score: 0.003
  178. Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. Am J Cardiol. 1997 Nov 01; 80(9):1183-7.
    View in: PubMed
    Score: 0.003
  179. No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Am J Med Genet. 1997 Apr 18; 74(2):192-4.
    View in: PubMed
    Score: 0.003
  180. No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol. 1997; 14(3):299-305.
    View in: PubMed
    Score: 0.003
  181. Prognostic importance of the length of ventricular tachycardia in patients with nonischemic congestive heart failure. Am Heart J. 1995 Sep; 130(3 Pt 1):489-93.
    View in: PubMed
    Score: 0.003
  182. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol. 1995 Mar 01; 75(7):460-4.
    View in: PubMed
    Score: 0.002
  183. Acute hemodynamic effects of atrio-biventricular pacing in humans. Ann Thorac Surg. 1995 Feb; 59(2):294-300.
    View in: PubMed
    Score: 0.002
  184. A home-based geriatric assessment, follow-up and health promotion program: design, methods, and baseline findings from a 3-year randomized clinical trial. Aging (Milano). 1994 Apr; 6(2):105-20.
    View in: PubMed
    Score: 0.002
  185. Racial differentials in the identification of hypercholesterolemia. J Fam Pract. 1993 Apr; 36(4):425-30.
    View in: PubMed
    Score: 0.002
  186. Electrophysiologic response to moricizine in patients with sustained ventricular arrhythmias. Ann Intern Med. 1992 Mar 01; 116(5):382-7.
    View in: PubMed
    Score: 0.002
  187. Barriers to cholesterol testing in a rural community. J Fam Pract. 1991 Jun; 32(6):614-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.